Research chemicalResearch chemicalPsychedelicLysergamide

AL-LAD

Also known as 6-allyl-6-nor-LSD · Aladdin

Written by enwyReviewed 15 Jul 20261 sources0 comments

AL-LAD (6-allyl-6-nor-LSD) is a lysergamide analogue of LSD carrying an allyl group in place of the N6 methyl. It is a potent psychedelic with an experience often described as slightly more visual and less anxiogenic than LSD, characterised in early animal work by Hofmann and later by Nichols but never clinically trialled.

01 Overview

AL-LAD is one of the better-known "designer" lysergamides, first prepared in academic laboratories exploring modifications of the LSD scaffold. It circulates as blotters and is one of the more commonly encountered LSD alternatives.

Reported effects resemble LSD with a comparable dose range but a subtly different character: many users describe more colourful visuals and a somewhat gentler headspace. All such comparisons are anecdotal; there are no controlled human studies, and the same core psychedelic risks apply.

02 Mechanism

Partial agonist at 5-HT2A and other serotonin receptors; the N6-allyl substitution modestly alters receptor interaction relative to LSD.

03 Dosing

Tier	Dose	Route	Notes
Threshold	10–25 mcg	Sublingual	Microdose range.
Common	80–150 mcg	Sublingual	Full psychedelic dose; roughly LSD-comparable.
Strong	150–300 mcg	Oral	Strong visual experience.

04 Effects

Effect	Magnitude	Evidence
Enhanced visualsVivid colour and geometric visuals, often reported as more pronounced than LSD.	6-10 h	Anecdotal
Mood elevationEuphoria and emotional openness with a headspace often called clearer than LSD.		Anecdotal
Anxiety at high dosesOverwhelm and paranoia possible at strong doses or in poor settings.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Sympathomimetic effectsRaised heart rate and blood pressure, pupil dilation and mild tremor.	Mild	Common	Anecdotal
Acute psychological distressAnxiety, paranoia or a challenging experience during acute effects.	Moderate	Common	Anecdotal
Persistent perceptual changes (HPPD)Lasting visual disturbances after use, as with other LSD-type drugs.	Moderate	Rare	Observational

06 Legal status

United Kingdom

Class A (Misuse of Drugs Act)

Controlled as a lysergamide. · as of Jan 2026

United States

Possible Schedule I analogue

May be treated as an LSD analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Nichols et al., synthesis and activity of LSD analogues (AL-LAD, ETH-LAD)PubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.